



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/033,526 | 11/02/2001 | Yadong Huang | UCAL217 | 7367 |

24353 7590 10/11/2002

BOZICEVIC, FIELD & FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK, CA 94025

EXAMINER

NICHOLS, CHRISTOPHER J

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 10/11/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|------------------------------|----------------------------|--------------|--|
| Office Action Summary | Application N . | Applicant(s) | |
| | 10/033,526 | HUANG ET AL. | |
| | Examiner | Art Unit | |
| | Christopher Nichols, Ph.D. | 1647 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 5 March 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-31 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-31 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-6, 23-24, 28, and 31, drawn to a method of inhibiting formation of neurofibrillary tangles in an individual said method comprising reducing formation of a truncated form of apoE, classification dependent upon agent structure.
 - II. Claims 7-11, drawn to a transgenic non-human animal, classified in class 800, subclass 9.
 - III. Claims 12-16, drawn to a method of screening for biologically active agents that modulate a phenomenon associated with Alzheimer's disease (AD) comprising using a non-human transgenic animal, classified in class 800, subclass 9.
 - IV. Claims 17-20, drawn to an isolated cell comprising a nucleic acid molecule that comprises a nucleotide sequence that encodes a carboxyl-terminal truncated form of apoE, classified in class 536, subclass 23.1, for example.
 - V. Claims 21 and 22, drawn to a method of inhibiting formation of neurofibrillary tangles in an individual, the method comprising inhibiting interaction of carboxyl-terminal truncated form of apoE with other components of a neurofibrillary tangle, classification dependent upon agent structure.
 - VI. Claim 26, drawn to a method of treating Alzheimer's disease the method comprising assaying for the presence of carboxyl-terminal truncated apoE in a neuronal cell and administering an inhibitor, classification dependent upon agent structure.

VII. Claims 25, 27, and 29-30, drawn to pharmaceutical compositions and kits comprising same, classification dependent upon inhibitor structure.

2. The inventions are distinct, each from the other because of the following reasons:

3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions I, III, V, and VI are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention I requires search and consideration of reducing formation of a truncated form of apoE, which is not required by any of the other Inventions. Invention III requires search and consideration of a screening assay using a non-human transgenic animal, which is not required by any of the other Inventions. Invention V requires search and consideration of inhibiting interaction of carboxyl-terminal truncated form of apoE with other components of a neurofibrillary tangle, which is not required by any of the other Inventions. Invention VI requires search and consideration of assaying for the presence of carboxyl-terminal truncated apoE, which is not required by any of the other Inventions

4. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these products constitute patentably distinct inventions for the following reasons. Inventions II, IV, and VI are directed to products that are distinct both physically and functionally, are not required one for the other, and are therefore patentably distinct. The isolated polypeptide of Invention II is independent and distinct from the products

of Inventions IV and VI because neither is required to make or use the transgenic non-human animal of Invention II. Although the isolated cell of Invention IV can be obtained from the non-human transgenic animal of Invention II it can also be made in materially different methods, such as transfection of a cell line with a vector. Additionally, the pharmaceutical compositions and kit of Invention VII is not required to make or use the isolated cell of Invention IV. The pharmaceutical compositions and kit of Invention VII are independent and distinct from the products of Inventions II and IV because neither is required to make or use the pharmaceutical compositions and kit of Invention VII.

5. Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The transgenic non-human animal of Invention II can be used to study onset and progression of Alzheimer's disease (a disease model).

6. Inventions VII and each of I and VI are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The pharmaceutical compositions and kit can be used to identify enzymes that catalyze the formation of carboxyl-terminal truncated apoE.

7. Inventions II and each of I, V, and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions II and each of I, V, and VI are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions I, V, and VI do not recite the use or production of the non-human transgenic animal of Invention II.

8. Inventions IV and each of I, III, V, and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions IV and each of I, III, V, and VI are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions I, III, V, and VI do not recite the use or production of the isolated cell of Invention IV.

9. Inventions VII and each of III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions VII and each of III and V are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions III and V do not recite the use or production of the pharmaceutical compositions and kit of Invention VII.

10. FURTHERMORE, restriction to one of the following inventions is required under 35

U.S.C. 121:

- A. Claims 1-31, each in part, as the inventions pertain to SEQ ID NO: 1.
- B. Claims 1-31, each in part, as the inventions pertain to SEQ ID NO: 2.
- C. Claims 1-31, each in part, as the inventions pertain to SEQ ID NO: 3.
- D. Claims 1-31, each in part, as the inventions pertain to SEQ ID NO: 4.

11. The inventions are distinct, each from the other because of the following reasons:

12. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different products, restriction is deemed to be proper because these products appear to constitute patentably distinct inventions for the following reasons: Inventions A, B, C, and D are directed to sequences that are distinct both physically and functionally, and are not required one for the other. Invention A requires search and consideration of SEQ ID NO: 1, which is not required by any of the other Inventions. Invention B requires search and consideration of SEQ ID NO: 2, which is not required by any of the other Inventions. Invention C requires search and consideration of SEQ ID NO: 3, which is not required by any of the other Inventions. Invention D requires search and consideration of SEQ ID NO: 4, which is not required by any of the other Inventions. Each sequence requires a separate search of the literature and sequence databases. A search and examination of an Invention as it pertains to all sequences would therefore present the examiner with an undue search burden.

13. Applicant is advised that this is not a requirement to elect a species. Rather, this is a second restriction requirement superimposed upon the requirement to elect one group from I-VII.

Art Unit: 1647

In order to be fully responsive, Applicant must elect one group from I-VII and one group from A-D.

14. This application contains claims directed to the following patentably distinct species of the claimed invention:

- a. Alzheimer's disease
- b. Coronary Artery disease
- c. Head trauma
- d. Stroke

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 4 is generic.

If applicant selects Invention I, one species from the disorder group must be chosen to be fully responsive.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

15. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
16. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.
17. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/033,526

Page 9

Art Unit: 1647

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher Nichols, Ph.D. whose telephone number is 703-305-3955. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN
October 10th, 2002

Elizabeth C. Kemmerer

ELIZABETH KEMMERER
PRIMARY EXAMINER